EU 2024/996 deadlines that hit in 2025: Vitamin A, arbutins, genistein, daidzein, kojic acid

Members

EUHigh riskReformulate

February 1, 2025

📅 Making available (selected 996 entries) · 1 Nov 2025

Original source

Regulation / act

Commission Regulation (EU) 2024/996 of 3 April 2024 amending Regulation (EC) No 1223/2009 as regards the use of Vitamin A, Alpha-Arbutin and Arbutin and certain substances with potential endocrine-disrupting properties

Official date: 2024-04-03
Official URL: Commission Regulation (EU) 2024/996 — Vitamin A, arbutins and certain potential EDs

Unlock the official file

Business Impact stays free. Paid plans unlock the original source, official text, and Regulatory Details — plus Workbench and Verify credits.

See membership plans

Official source. Regulation (EU) 2024/996

Key points

Annex II/III changes for Vitamin A, arbutins, genistein, daidzein, kojic acid, 4-MBC and related entries.
Staggered placing-on-the-market and making-available dates — 1 Feb 2025 and 1 Nov 2025 are the ones that fell inside this desk year.
Vitamin A has product-type concentration caps and warning language; read the annex row, not a blog table.

Dates. OJ 4 April 2024. Key 2025 dates: 1 February (place) and 1 November (make available) for listed entries — confirm each row.

Verify in the official text. Per-substance annex row, product type, and warning statements.

Open questions. Confirm any transitional stock rules and whether your exact INCI / product type is named. This desk brief is a prioritisation aid, not a legal determination.

What changed: 2024/996 concentration and ban rows became commercially real in 2025.

Who is affected: Retinoid, arbutin, kojic, soy-isoflavone and 4-MBC formulas in the EU.

Suggested next steps: Audit 3PL for pre-996 strengths; keep CPSR and CPNP in sync with the new max.

Regulation (EU) 2024/996 reset limits for Vitamin A (retinol, retinyl acetate, retinyl palmitate), alpha-arbutin, arbutin, genistein, daidzein, kojic acid and 4-MBC.
The first placing-on-the-market date for several entries was 1 February 2025; making available on 1 November 2025. If you still have EU retail inventory of old retinoid or arbutin strengths, it should already have been pulled.
This week: confirm no 3PL still holds pre-996 formulas as “available” in the Union.

Official text

Extract from the official English instrument

Official English extract from Regulation (EU) 2024/996. Each annex row and its own dates prevail.

Commission Regulation (EU) 2024/996 of 3 April 2024 amends Regulation (EC) No 1223/2009 as regards the use of Vitamin A, Alpha-Arbutin and Arbutin and certain substances with potential endocrine-disrupting properties.

The act amends Annexes II and/or III in respect of, among others, retinol, retinyl acetate, retinyl palmitate, alpha-arbutin, arbutin, genistein, daidzein, kojic acid and 3-(4′-methylbenzylidene)camphor, with the restrictions, maximum concentrations and wording set out in those annex entries.

The regulation sets staggered transitional dates by entry, including 1 February 2025 (placing on the market) and 1 November 2025 (making available) for specified entries. The date that applies is the date written against that substance row.

EU 2024/996 deadlines that hit in 2025: Vitamin A, arbutins, genistein, daidzein, kojic acid

Original source

Regulatory Details

Business Impact

Official text

Intelligence

Company

Legal

Original source

Business Impact

Related updates